June 2026 saw drug development in oncology and neurology continue and biotech deals over small molecules and RNA therapies ...

Delve into the hidden innovation system of drug repurposing. When patents expire and commercial value fades, a new wave of ...

Parabilis Medicines, NewLimit, Enliven Therapeutics, and Kardigan bagged the biggest biotech funding rounds overall in June 2026.

Find out what Novartis' pipeline strategy since it spun off its biosimilars and generics business Sandoz, and engage in ...

Discover Prague's biotech hub, now viewed as the primary ‘entry gateway’ into the wider Central and Eastern European ...

The European life science sector remains a key driver of global innovation that is propelled by technological breakthroughs and a robust pipeline of novel therapies. But the European Union (EU) is ...

So far, the visible strategy around bronchiectasis has been managing the problems it creates — mucus retention, repeated infections, airway inflammation, and exacerbations. Airway clearance, ...

There was a time when the numbers told an unoptimistic story about Roche. Its three oncology blockbusters, Herceptin, Avastin, and Rituxan, had built it into the world’s largest cancer drug maker, ...

Earlier this month Labiotech published its roundup of the top biotech deals for May 2026. Heading the list was Angelini Pharma’s $4.1 billion acquisition of Catalyst Pharmaceuticals, just ahead of UCB ...

In vivo CAR-T therapies have grown in demand over the years, as scientists have figured out how to crack the challenges of target specificity and safety, proving to be more efficient than ex vivo ...